Abstract
We studied the association of the serum levels of the microRNA family members miR-320a/-b/-c with clinico-pathological data to assess their applicability as diagnostic biomarker in prostate cancer (PCa) patients. The levels of miR-320a/-b/-c in 3 groups were evaluated by qRT-PCR (145 patients with PCa, 31 patients with benign prostatic hyperplasia (BPH) and 19 healthy controls). The levels of the three family members of miR-320 were directly correlated within each group (P < 0.001), but they differed significantly among the three groups (P < 0.001). The serum levels of the miR-320 family members were significantly increased in older patients compared to younger patients (≤ 66 years vs. > 66 years, P ≤ 0.001). In addition, the levels of all three miR-320 family members were significantly different in patients with low tumor stage compared with those with high tumor stage (miR-320a: P = 0.034; miR-320b: P = 0.006; miR-320c: P = 0.007) and in patients with low serum PSA compared with those with high serum PSA (≤ 4 ng vs. > 4 ng; miR-320a: P = 0.003; miR-320b: P = 0.003; miR-320c: P = 0.006). The levels of these miRNAs were inversely correlated with serum PSA levels. Detection in the serum samples of PCa patients with or without PSA relapse revealed higher levels of miR-320a/-b/-c in the group without PSA relapse before/after radical prostatectomy than in that with PCa relapse.In summary, the differences among the PCa/BPH/healthy control groups with respect to miR-320a/-b/-c levels in conjunction with higher levels in patients without a PSA relapse than in those with a relapse suggest the diagnostic potential of these miRNA-320 family members in PCa patients.
Highlights
The microRNA miR-320 family is conserved, but only exists in vertebrates from Xenopus to humans
To study miR-320 family members and their association with clinico-pathological parameters as well www.impactjournals.com/oncotarget www.impactjournals.com/oncotarget as their diagnostic and prognostic utility, we analyzed serum samples obtained from liquid biopsies
The levels of miR-320a/-b/-c in serum samples from patients with prostate cancer (PCa), patients with benign prostatic hyperplasia (BPH) and healthy controls were significantly different, which suggests that all three miRNAs may serve as diagnostic biomarkers
Summary
The microRNA miR-320 family is conserved, but only exists in vertebrates from Xenopus to humans. The diagnostic utility of decreased miR-320 in the peripheral blood of glioblastoma patients compared with healthy probands has been shown [19] The downregulation of this miRNA was further associated with more aggressive behavior and/or poor prognosis in SCLC [10], colon cancer [11], breast cancer [3, 4], and cervical cancer [17]. An association between reduced miR-320a transcript levels in tumor tissue and a poor overall survival for prostate cancer patients was reported [15] Taken together, this evidence shows the involvement of the miR-320 family in cancer development and progression, it suggests the potential use of this microRNA family in clinical practice. An association of miR-320 family members with clinicopathological data and their utility as diagnostic serum markers have not yet been studied in prostate cancer patients comprehensively
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
